| Project/Area Number |
26861135
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Respiratory surgery
|
|---|
| Research Institution | National Cardiovascular Center Research Institute |
|---|
Principal Investigator |
Kimura Toru 国立研究開発法人国立循環器病研究センター, 研究所, 流動研究員 (90580796)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 肺外科 / 間質性肺炎 / 肺線維症 / 急性増悪 / ナトリウム利尿ペプチド |
|---|
| Outline of Final Research Achievements |
We first developed a new mouse model of acute exacerbation (AE) of interstitial lung disease (ILD) for further investigation of prophylactic interventions. Secondly, our study revealed that C-type natriuretic peptide (CNP) had anti-inflammatory effect against LPS-induced acute lung injury mode (as one of the inflammatory stimulation models which induce AE) and anti-fibrotic effect against BLM-induced pulmonary fibrosis model. Additionally, our data suggest that CNP ameliorates bleomycin- induced pulmonary fibrosis by suppressing TGF-β signaling and myofibroblastic differentiation in lung fibroblasts. Therefore, we propose consideration of CNP for clinical application to treatment for pulmonary fibrosis and its exacerbation.
|
